section name header

Pronunciation ⬇

BIZ-muth sub-sa-LIS-i-late

Classifications ⬆ ⬇

Therapeutic Classification: antidiarrheals, antiulcer agents

Pharmacologic Classification: adsorbents

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Promotes intestinal adsorption of fluids and electrolytes.
  • Decreases synthesis of intestinal prostaglandins.
Therapeutic effects:
  • Relief of diarrhea.
  • Eradication of H. pylori with decreased recurrence of ulcer disease (with other agents).

Pharmacokinetics ⬆ ⬇

Absorption: Bismuth is not absorbed; salicylate split from parent compound is >90% absorbed from the small intestine.

Distribution: Salicylate is well distributed to tissues.

Protein Binding: Bismuth and salicylate >90%.

Metabolism/Excretion: Bismuth is excreted unchanged in the feces. Salicylate undergoes extensive hepatic metabolism.

Half-Life: Salicylate:2–3 hr for low doses; 15–30 hr with larger doses.

Time/Action Profile ⬆ ⬇

(relief of diarrhea and other GI symptoms)

ROUTEONSETPEAKDURATION
POwithin 24 hrunknownunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: constipation, gray-black stools/tongue, impaction

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Pepto-Bismol

Code ⬆

NDC Code